Clinical Trials Compliance Patients Therapy 
Cannabis Law Report
AUGUST 18, 2022
The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.
Cannabis Law Report
AUGUST 7, 2021
We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. Key Responsibilities.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MMJ Recs
JULY 9, 2024
Patients often struggle with symptoms that range from physical discomfort to cognitive impairment. In this article, we explore how medical marijuana for multiple sclerosis symptoms helps patients, with its diverse cannabinoid components, alleviate MS symptoms, and enhance the quality of life for patients.
Cannabis Law Report
MAY 31, 2022
Two approaches apply to commercial operations—the traditional medical path and the emerging non-medical state-regulated path, while the other two paths are better seen as non-commercial—underground therapy and religious use. The first path, that of traditional medicine, currently offers patients limited options. Breakthrough Therapy.
Cannabis Law Report
NOVEMBER 19, 2021
MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Key Responsibilities.
Cannabis Law Report
OCTOBER 2, 2021
We are currently focused on developing MDMA-assisted therapy as a Breakthrough Therapy for PTSD, with plans to submit for FDA approval in 2023. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.
Cannabis Law Report
JUNE 20, 2021
The CIC consists of 97 members dedicated to ensuring a greater understanding of the role of medicinal cannabis, nutraceutical CBD, and hemp across the community and the advancement of medicinal cannabis as an alternate line of therapy. Patient access.
Expert insights. Personalized for you.
52 
Let's personalize your content